A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

BRCA1 and BRCA2 gene mutations increase the risk of hereditary breast cancer. Here's what you should know about the causes, ...

Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after mastectomy were 16 times more likely ...

An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...

Risk assessments for cancers related to BRCA mutations could save lives. Annually, about 247,200 cases of breast cancer are diagnosed in the U.S. and nearly 42,000 people die each year from breast ...

Patients with BRCA-mutant breast cancer had a significantly higher risk of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL), a large cohort study showed. BRCA1/2 mutations conferred ...

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A ...

Here’s some encouraging news for women whose family members carry the BRCA gene mutations that increase the risk of breast cancer: if you don’t have the mutations yourself, your risk of developing the ...

(WASHINGTON, June 13, 2025) – Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after ...

Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more pronounced pathologic ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...